Sanofi stock holds steady as healthcare demand supports long-term growth

• Researchers from the University of Adelaide found that intermittent fasting is as effective for weight loss as traditional calorie restriction. • An 18-month clinical trial involving over 200 adults with obesity demonstrated that fasting requires significantly less mental effort than constant calorie counting.

• New clinical trials have been launched in the Democratic Republic of Congo to evaluate the efficacy of two drugs, MBP-134 and remdesivir, against the Bundibugyo Ebola virus. • These trials are critical because the Bundibugyo species currently lacks any approved vaccines or therapies to mitigate its spread.

• Oxford University has launched Phase 1 human trials for a new Ebola vaccine targeting the Bundibugyo strain, supported by CEPI. • The Serum Institute is producing over 620,000 doses, with the trial beginning just 57 days after the WHO declared the outbreak a Public Health Emergency of International Concern.

• The Oxford Vaccine Group has launched the world's first Phase I clinical trial for a vaccine targeting the Bundibugyo ebolavirus. • The initiative is being supported by India's Serum Institute to develop a viable immunization strategy against this specific strain.

• Researchers have identified new threats of flesh-eating bacteria in summer waters, coinciding with a broader decline in public health oversight. • Dr. Jha warns that the Trump administration is dismantling critical policies and incentives intended to combat the nationwide chronic disease epidemic.

• The World Health Organization (WHO) projects that new cancer cases will nearly double by 2050, with the disease currently claiming over 26,000 lives daily worldwide. • Separate research indicates that ketogenic therapy may improve both physical health and cognitive performance in patients with serious mental illnesses.

• The FDA has approved the use of Paxlovid for children aged 12 and older who weigh at least 88 pounds. • AstraZeneca reported that its heart disease drug failed a pivotal trial, marking a significant setback in the company's cardiovascular development goals.

• Public health officials have issued an alert regarding a multistate rise in cyclosporiasis, a parasitic gastrointestinal illness, with over 450 reported cases across 18 states. • Michigan is the most heavily impacted region, accounting for more than 300 of the total cases, though officials warn the actual number is likely higher due to underreporting.

• Poison control center calls involving semaglutide drugs, including Ozempic and Wegovy, have surged following their approval for weight management. • Researchers indicate that the spike in reports is primarily linked to accidental dosing errors rather than intentional misuse.

• Researchers are investigating whether the four-component meningococcal serogroup B vaccine (4CMenB) can prevent infections caused by Neisseria gonorrhoeae, as no licensed vaccines currently exist for the disease. • The study, supported by GSK and the Australian National Health and Medical Research Council (grant GNT1182443), relies on observational data to determine if the vaccine provides cross-protection.

• The FDA approved five first-in-class therapies during the first half of 2026, targeting obesity, AML, kidney disease, hearing loss, and bladder cancer. • On April 14, Travere Therapeutics received approval for sparsentan (Filspari), the first treatment specifically approved for focal segmental glomerulosclerosis (FSGS), a rare kidney disease.